Comments on “Week 2 remission with vedolizumab as a predictor of long-term remission in patients with ulcerative colitis: a multicenter, retrospective, observational study”

with vedolizumab is associated with higher rates of week 52 remission, a substantial proportion of delayed responders (remission at week 14) also achieve favorable long-term outcomes.These findings, echoed in real-world studies, caution against premature discontinuation of vedolizumab based solely on early non-response, given the agent' s delayed onset of action and the existence of late responders.To further inform clinical decision-making, we calculated the predictive metrics for week 2 remission as a predictor of week 54 remission using the data presented in Fig. 2A of the article.The sensitivity was 58%, specificity 60%, PPV 70%, and NPV 47%.These findings indicate that while week 2 remission is associated with favorable long-term outcomes, the absence of early remission does not reliably exclude the possibility of later clinical benefit.This is consistent with our previous findings, 4 which demonstrated that early symptomatic improvement at week 2 predicted clinical response, remission, and mucosal healing at week 10, but that some patients without early response still achieved favorable outcomes.We therefore recommend that future studies report these metrics and consider decision-analytic approaches to better guide therapy optimization.In summary, while week 2 remission is a statistically significant prognostic marker, its clinical application as a decision point should be supported by robust quantitative predictive metrics and integrated into evidence-based decision frameworks.We encourage the authors and future investigators to report these metrics and to contextualize early response with-